Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program   – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...